icon fsr

文献詳細

雑誌文献

精神医学66巻4号

2024年04月発行

文献概要

特集 精神疾患・精神症状にはどこまで脳器質的背景があるのか—現代の視点から見直す

統合失調症と自己抗体

著者: 塩飽裕紀1

所属機関: 1東京医科歯科大学大学院精神行動医科学分野

ページ範囲:P.376 - P.382

文献購入ページに移動
抄録
 統合失調症にはさまざまな背景病態があり異種性が指摘されている。背景病態の候補の1つが自己免疫・自己抗体に関連するものである。神経系に対する自己抗体は,自己免疫性脳炎における抗N-メチル-D-アスパラギン酸(NMDA)受容体抗体の発見を皮切りに,さまざまな神経系の分子に対する自己抗体が発見されるようになった。その後,急性精神病における自己抗体の存在から自己免疫性精神病の概念を経て,統合失調症でも神経系に対する自己抗体が報告されるようになり,統合失調症における自己抗体病態がさらに検証されるようになってきている。本稿では,われわれが発見したシナプス分子に対する新規自己抗体である抗NCAM1自己抗体や抗NRXN1自己抗体をはじめ,統合失調症における新規の自己抗体とその探索アプローチを概観し,自己抗体が統合失調症でどのような病態を形成するかを考察する。さらに統合失調症における自己抗体病態に対する治療の今後についても考察する。

参考文献

1)Sekar A, Bialas AR, de Rivera H, et al:Schizophrenia Working Group of the Psychiatric Genomics Consortium:Schizophrenia risk from complex variation of complement component 4. Nature 530:177-183, 2016[PMID:26814963]
2)Sellgren CM, Gracias J, Watmuff B, et al:Increased synapse elimination by microglia in schizophrenia patient-derived models of synaptic pruning. Nat Neurosci 22:374-385, 2019[PMID:30718903]
3)Schizophrenia Working Group of the Psychiatric Genomics Consortium:Biological insights from 108 schizophrenia-associated genetic loci. Nature 511:421-427, 2014[PMID:25056061]
4)Cullen AE, Holmes S, Pollak TA, et al:Associations between non-neurological autoimmune disorders and psychosis:A meta-analysis. Biol Psychiatry 85:35-48, 2019[PMID:30122288]
5)Hansen N, Lipp M, Vogelgsang J, et al;CAP(Cerebrospinal Fluid Analysis in Psychiatry)Consortium:Autoantibody-associated psychiatric symptoms and syndromes in adults:A narrative review and proposed diagnostic approach. Brain Behav Immun Health 9:100154, 2020[PMID:34589896]
6)Dalmau J, Tüzün E, Wu HY, et al:Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 61:25-36, 2007[PMID:17262855]
7)Pollak TA, Lennox BR, Müller S, et al:Autoimmune psychosis:An international consensus on an approach to the diagnosis and management of psychosis of suspected autoimmune origin. Lancet Psychiatry 7:93-108, 2020[PMID:31669058]
8)Nakagami Y, Sugihara G, Nakashima N, et al:Anti-PDHA1 antibody is detected in a subset of patients with schizophrenia. Sci Rep 10:7906, 2020[PMID:32404964]
9)Zandian A, Wingård L, Nilsson H, et al:Untargeted screening for novel autoantibodies with prognostic value in first-episode psychosis. Transl Psychiatry 7:e1177, 2017[PMID:28742074]
10)Jernbom Falk A, Galletly C, Just D, et al:Autoantibody profiles associated with clinical features in psychotic disorders. Transl Psychiatry 11:474, 2021[PMID:34518517]
11)Whelan R, St Clair D, Mustard CJ, et al:Study of novel autoantibodies in schizophrenia. Schizophr Bull 44:1341-1349, 2018[PMID:29373732]
12)Shiwaku H, Katayama S, Kondo K, et al:Autoantibodies against NCAM1 from patients with schizophrenia cause schizophrenia-related behavior and changes in synapses in mice. Cell Rep Med 3:100597, 2022[PMID:35492247]
13)Shiwaku H, Katayama S, Gao M, et al:Analyzing schizophrenia-related phenotypes in mice caused by autoantibodies against NRXN1α in schizophrenia. Brain Behav Immun 111:32-45, 2023[PMID:37004758]
14)Wood GK, Tomasiewicz H, Rutishauser U, et al:NCAM-180 knockout mice display increased lateral ventricle size and reduced prepulse inhibition of startle. Neuroreport 9:461-466, 1998[PMID:9512390]
15)Brennaman LH, Kochlamazashvili G, Stoenica L, et al:Transgenic mice overexpressing the extracellular domain of NCAM are impaired in working memory and cortical plasticity. Neurobiol Dis 43:372-378, 2011[PMID:21515372]
16)Marshall CR, Howrigan DP, Merico D, et al:Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects. Nat Genet 49:27-35, 2017[PMID:27869829]
17)Singh T, Poterba T, Curtis D, et al:Rare coding variants in ten genes confer substantial risk for schizophrenia. Nature 604:509-516, 2022[PMID:35396579]
18)Yang C, Hou X, Feng Q, et al:Lupus serum IgG induces microglia activation through Fc fragment dependent way and modulated by B-cell activating factor. J Transl Med 17:426, 2019[PMID:31864410]
19)Dalakas MC, Alexopoulos H, Spaeth PJ:Complement in neurological disorders and emerging complement-targeted therapeutics. Nat Rev Neurol 16:601-617, 2020[PMID:33005040]
20)Carvajal-González A, Leite MI, Waters P, et al:Glycine receptor antibodies in PERM and related syndromes:Characteristics, clinical features and outcomes. Brain 137(Pt 8):2178-2192, 2014[PMID:24951641]
21)Körtvelyessy P, Bauer J, Stoppel CM, et al:Complement-associated neuronal loss in a patient with CASPR2 antibody-associated encephalitis. Neurol Neuroimmunol Neuroinflamm 2:e75, 2015[PMID:25738171]
22)Stevens B, Allen NJ, Vazquez LE, et al:The classical complement cascade mediates CNS synapse elimination. Cell 131:1164-1178, 2007[PMID:18083105]
23)Forsyth JK, Lewis DA:Mapping the consequences of impaired synaptic plasticity in schizophrenia through development:An integrative model for diverse clinical features. Trends Cogn Sci 21:760-778, 2017[PMID:28754595]
24)Rahman KA, Orlando M, Boulos A, et al:Microglia actively remove NR1 autoantibody-bound NMDA receptors and associated post-synaptic proteins in neuron microglia co-cultures. Glia 71:1804-1829, 2023[PMID:37026600]
25)Onwordi EC, Halff EF, Whitehurst T, et al:Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in rats. Nat Commun 11:246, 2020[PMID:31937764]
26)Pollak TA, Vincent A, Iyegbe C, et al:Relationship between serum NMDA receptor antibodies and response to antipsychotic treatment in first-episode psychosis. Biol Psychiatry 90:9-15, 2021[PMID:33536130]
27)Shiwaku H, Nakano Y, Kato M, et al:Detection of autoantibodies against GABAARα1 in patients with schizophrenia. Schizophr Res 216:543-546, 2020[PMID:31806526]
28)Bejerot S, Sigra Stein S, Welin E, et al:Rituximab as an adjunctive treatment for schizophrenia spectrum disorder or obsessive-compulsive disorder:Two open-label pilot studies on treatment-resistant patients. J Psychiatr Res 158:319-32, 2023[PMID:36638622]

掲載誌情報

出版社:株式会社医学書院

電子版ISSN:1882-126X

印刷版ISSN:0488-1281

雑誌購入ページに移動
icon up
あなたは医療従事者ですか?